The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer

Cancer Treatment Reviews

Volumn 34, Issue 8, 2008, Pages 710-718

  Petrioli, Roberto ^a   Fiaschi, Anna Ida ^a   Francini, Edoardo ^a   Pascucci, Alessandra ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Anthracyclines; Bone metastases; Doxorubicin; Epirubicin; Hormone refractory; Prostate cancer

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUOROURACIL; HYDROCORTISONE; KETOCONAZOLE; MACROGOL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; SURAMIN; TAXANE DERIVATIVE; VINBLASTINE;

ACUTE HEART INFARCTION; ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BONE NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 56249147452     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.05.004     Document Type: Review

References (86)

1. Eisenberger M.A., Simon R., O'Dwyer P.J., et al. J Clin Oncol 3 (1985) 827-841
2. Millikan R.E. Chemotherapy of advanced prostate cancer. Semin Oncol 26 (1999) 185-191
3. Slack N.H., and Murphy G.P. Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 11 (1984) 337-342
4. Dawson N.A. Apples and oranges: building a consensus for standardized eligibility criteria and endpoints in prostate cancer clinical trials. J Clin Oncol 16 (1998) 3305-3398
5. Francini G., Petrioli R., Gonnelli S., et al. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 92 (2001) 1468-1474
6. Collette L., Burzykowski T., and Schroder F.H. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42 (2006) 1344-1350
7. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351 15 (2004) 1502-1512
9. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351 (2004) 1513-1520
10. Galsky M.D., Small E.J., Oh W.K., et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 (2005) 1746-1749
11. Ning Y.M., Arlen P., Gulley J., et al. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol 18S (2007) [Abstract 5114]
12. Beer T.M., Ryan C.W., Venner P.M., et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112 (2008) 326-330
13. Harzstark A.L., and Ryan C.J. Novel therapeutic strategies in development for prostate cancer. Expert Opin Invest Drugs 17 (2008) 13-22
14. Tewey K.M., Rowe T.C., Yang L., et al. Science 226 (1984) 446-468
15. Tu S.M., McConnell K., Marin M.C., et al. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93 (1995) 147-155
16. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 (1992) 6940-6944
17. Myers C.E., McGuire W.P., Liss R.H., et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197 (1977) 165-169
18. Robert J., and Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. 17 (1993) 219-252
19. Danesi R., Fogli S., Gennari A., Conte P., and Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41 (2002) 431-444
20. Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45 suppl 2 (1993) 20-30
21. DeWys A.J., Bauer M., Colsky J., et al. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer - progress report. Cancer Treat Rep 61 (1977) 325-328
22. Scher H., Yagoda A., Watson R.C., Serber M., and Whitmore W. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131 (1984) 1099-1102
23. Fossa S.D., Urnes T., and Kaalhus O. Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate. Scand J Urol Nephrol 21 (1987) 13-16
24. Torti F.M., Aston D., Lum B.L., et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1 (1983) 477-482
25. Burk K. Weekly chemotherapeutic regimen in metastatic prostate cancer. In: Therapeutic progress in urological cancers. Alan R.Liss. Inc.; 1989, p. 261-75.
26. Delaere K.P.J., Leliefeld H., Peulen F., et al. Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma. Br J Urol 70 (1992) 641-642
27. Elomaa I., Kellokumpu-Lehtinen P., Rannikko S., and Alfthan O. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol 19 (1991) 12-15
28. Rangel C., Matzkin H., and Soloway M.S. Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 39 (1992) 577-582
29. Tannock I.F., Erwin T.J., Stewart D.J., Fontaine B., and Gupta S. Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease. Am J Clin Oncol 16 (1993) 156-158
30. Brausi M., Jones W.G., Fossa S.D., et al. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer 31A (1995) 1622-1626
31. Francini G., Bigazzi S., Leone V., and Gennari C. Serum osteocalcin concentration in patients with prostatic cancer. Am J Clin Oncol suppl 2 (1988) 83-87
32. Francini G., Petrioli R., Manganelli A., et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67 (1993) 1430-1436
33. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 91 (1979) 710-717
34. Chlebowsky R.T., Paroly W.S., Pugh R.P., et al. Adryamicin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64 (1980) 47-51
35. Torti F.M., Bristow M.R., Howes A.E., et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Int Med 99 (1983) 745-749
36. Torti F.M., Bristow M.M., Lum B.L., et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46 (1986) 3722-3727
37. Billingham M.E., and Torti F.M. Endomyocardial biopsy findings in epirubicin therapy. Clin Trial J 24 (1987) 69-82
38. Petrioli R., Fiaschi A.I., Pozzessere D., et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 87 (2002) 720-725
39. Francini G., Paolelli L., Francini E., et al. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur J Surg Oncol 34 (2008) 216-221
40. Neri B., Barbagli G., Bellesi P., et al. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer. Anticancer Res 17 (1997) 3817-3820
41. van Andel G., Fernandez de Moral P., Caris C.T.M., et al. A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol 21 (2003) 177-182
42. Ihde D.C., Bunn P.A., Cohen M.H., et al. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression. Cancer 45 (1980) 1300-1310
43. Saxman S., Ansari R., Drasga R., et al. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. Cancer 70 (1992) 2488-2492
44. Stephens R.L., Vaughn C., Lane M., et al. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group Study. Cancer 53 (1984) 406-410
45. Murphy G.P., Priore R.L., and Scardino P.T. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. Urology 32 (1988) 33-40
46. Small E.J., Srinivas S., Egan B., Mcmillan A., and rearden T.P. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14 (1996) 1617-1625
47. Torti F.M., Shortliffe L.D., Carter S.K., et al. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 56 (1985) 2580-2586
48. Logothetis C.J., Samuels M.L., von Eschenbach A.C., et al. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1 (1983) 368-378
49. Babaian R.J., and Hsu S.D. Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C. Urology XXIII (1984) 272-275
50. Kasimis B.S., Miller B., Kaneshiro C., et al. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM′) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 3 (1985) 385-392
51. Laurie J.A., Hahn R.G., Therneau T.M., et al. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 69 (1992) 1440-1444
52. Blumenstein B., Crawford E.D., Saiers J.H., et al. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group Study. J Urol 150 (1993) 411-413
53. Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12 (1994) 683-688
54. Kelly W.K. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 34 suppl 3 (1998) 18-23
55. Ellerhorst J.A., Tu S.-M., Amato R.J., et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3 (1997) 2371-2376
56. Millikan R., Thall P.F., Lee S.-J., et al. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21 (2003) 878-883
57. Di Leo A., Bajetta E., Buzzoni R., et al. Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. Am J Clin Oncol 18 (1995) 239-244
58. Anderström C., Eddeland A., Folmerz P., et al. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. Eur Urol 27 (1995) 301-305
59. Fruehauf J.P., Myers C.E., and Sinha B.K. Synergistic activity of suramin with tumor necrosis alpha and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 18 (1990) 1206-1209
60. Miglietta L., Canobbio L., Granetto C., et al. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 123 (1997) 407-410
61. Falcone A., Antonuzzo A., Danesi R., et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 86 (1999) 470-476
62. Hernes E.H., Fossa S.D., Vaage S., et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Br J Cancer 76 (1997) 93-99
63. Culine S., Kattan J., Zanetta S., et al. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol 21 (1998) 470-474
64. Haas N.B., Manola J., Hudes G., et al. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol 23 (2000) 589-592
65. Veronesi A., Lo Re G., Foladore S., et al. Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. Eur Urol 29 (1996) 434-438
66. Huan S.D., Stewart D.J., Aitken S.E., Segal R., and Yau J.C. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 22 (1999) 471-474
67. Chao D., von Schlipple M., and Harland S.J. A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Eur J Cancer 33 (1997) 1230-1233
68. Odrazka K., Vaculikova M., Petera J., et al. Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer. Int J Urol 10 (2003) 387-391
69. Leaf A.N., Propert K., Corcoran C., et al. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882). Med Oncol 20 (2003) 137-145
70. Birtle A.J., Newby J.C., and Harland S.J. Epirubicin, carboplatin and 5-fluorouracil (EcarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer 91 (2004) 1472-1476
71. Borden L.S., Clark P.E., Lovato J., et al. Vinorelbine, doxorubicin and prednisone in androgen-independent prostate cancer. Cancer 107 (2006) 1093-1100
72. Neri B., Cipriani G., Fulignati C., et al. Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: a report of a phase II trial. Anti-Cancer Drugs 16 (2005) 63-66
73. Petrioli R., Paolelli L., Francini E., et al. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology 69 (2007) 142-146
74. Pagani O., Sessa C., Nole F., et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11 (2000) 985-991
75. Burdette-Radoux S., Wood M.E., Olin J.J., et al. Phase I/II trial of adjuvant dose dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer. Breast J 13 (2007) 274-280
76. Albertsson P., Lennernas B., and Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF-A. Acta Oncol 45 (2006) 144-155
77. Damber J.-E., Vallbo C., Albertsson P., et al. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58 (2006) 354-360
78. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
79. Hubert A., Lyass O., Pode D., and Gabizon A. Doxil (Caelix): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11 (2000) 123-127
80. R) in symptomatic androgen-independent prostate cancer (AIPC). Scand J Urol Nephrol 36 (2002) 34-39
81. McMenemin R., Macdonald G., Moffat L., and Bisset D. A phase II study of Caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest New Drugs 20 (2002) 331-337
82. Heidenreich A., Sommer F., Ohlmann C.H., et al. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101 (2004) 948-956
83. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 0182 study. J Clin Oncol 17 (1999) 2506-2513
84. Font A., Murias A., Arroyo F.R., et al. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 16 (2005) 419-424
85. Galli L., Fontana A., Galli C., et al. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer 97 (2007) 1613-1617
86. Ohlmann CH, Breitenbach K, Pfister D, et al. Docetaxel (DOC) and mitoxantrone (MIT) in the management of hormone-refractory prostate cancer (HRPCA). In: Proceedings of the prostate cancer symposium; 2007 [Abstract 242].